Brepocitinib improved dermatomyositis skin disease and itch from week 4

Design

Prespecified secondary analysis of a phase 3, double-blind, placebo-controlled randomised trial, 52 weeks

Population

241 adults with dermatomyositis and active skin and muscle disease

Primary outcome

Change in CDASI-A skin activity score

Effect

30 mg vs placebo: −3.0 (95% CI −4.6 to −1.4); itch remission 38.3% vs 19.0%

VALOR was a 52-week phase 3, double-blind, placebo-controlled trial of brepocitinib, an oral TYK2 and JAK1 inhibitor, in 241 adults with dermatomyositis and active skin and muscle disease across 90 sites in 20 countries. This prespecified secondary analysis looked at skin outcomes.

With 30 mg daily, skin disease activity (CDASI-A) fell more than with placebo from week 4 (−6.4 vs −3.5; difference −3.0, 95% CI −4.6 to −1.4). A clinically meaningful skin response was reached by 33.3% against 17.7% (difference 15.1 percentage points, 1.7–28.6), and itch remission by 38.3% against 19.0% (18.9 points, 5.0–32.9). Among the 155 with moderate to severe skin disease, 45.7% against 21.8% were clear or almost clear at week 52. The safety profile was described as consistent with approved JAK and TYK2 inhibitors.

Cutaneous dermatomyositis is often the most refractory part of the disease and itch drives much of the burden, so a drug acting on both is relevant. The drug was investigational in this trial and several of these outcomes were exploratory.

• Measure skin activity and itch separately from muscle disease at each review
• Keep dermatomyositis skin disease in view when muscle strength has recovered
• Screen for malignancy and interstitial lung disease regardless of skin response
• Watch for regulatory decisions before counting brepocitinib as an option

Why it matters

Skin disease in dermatomyositis often outlasts muscle response, and this is controlled evidence for an oral agent targeting it.

Don't overread it

These were secondary and exploratory outcomes of the trial, not its primary endpoint.

The statistics, in plain English

A 15 percentage point difference in response means about one extra responder for every seven patients treated. The intervals are wide — 1.7 to 28.6 points — because each arm had only about 80 patients, so the true benefit could be much smaller or larger. Itch and clear-skin outcomes were exploratory, so they support the main result rather than stand alone.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.